Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N02 ANALGESICS
N02B OTHER ANALGESICS AND ANTIPYRETICS
N02BF Gabapentinoids
N02BF01 Gabapentin
D09539 Gabapentin enacarbil (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Central Nervous System, Other
Gabapentin
D09539 Gabapentin enacarbil (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D09539 Gabapentin enacarbil (JAN/USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01574 Calcium channel alpha-2 delta blocker
DG01245 Gabapentin
D09539 Gabapentin enacarbil
DG03199 Antiepileptic agent
DG02037 GABA mimetic antiepileptic
DG01245 Gabapentin
D09539 Gabapentin enacarbil
Drug classes [BR:br08332]
Neuropsychiatric agent
DG03199 Antiepileptic agent
D09539 Gabapentin enacarbil
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Calcium channels
CACNA2D
D09539 Gabapentin enacarbil (JAN/USAN/INN) <JP/US>
Transporters
Solute carrier family
SLC6
SLC6A1 (GAT1)
D09539 Gabapentin enacarbil (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09539
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09539
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09539
Prodrugs [br08324.html]
D09539
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01574 Calcium channel alpha-2 delta blocker
DG01245 Gabapentin
DG03199 Antiepileptic agent
DG02037 GABA mimetic antiepileptic
DG01245 Gabapentin